Optieum Biotechnologies

Japan
Matsuyama, Ehime, Japan, 791-0204

Company profile

Optieum Biotechnologies company profile

Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers. Their proprietary platform technology, Eumbody System™, enables to develop and detect a scFv-based product candidates that specifically bind to, and modulate to optimize the immune-cell function for oncology targets. We are committed to helping patients with severe diseases by bringing life-changing therapies to the patients in need.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2020-03-01

Headquarters

Postal code
791-0204
Country code
JP
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$11M
Last funding
Series A / $8.4M / 2025-01-14
Last equity funding
Series A / $8.4M
Investors
7
Lead investors
2
Articles
1

Founders and investors

Lead investors

ANRISaisei Ventures

Investors

ANRIIyogin CapitalKeio Innovation InitiativeSaisei VenturesUntroD Capital